Navigation Links
Skinvisible Appoints New Board Member

- Brian Piwek to Assist in Generating New Retail Licensing Opportunities

LAS VEGAS, Feb. 1 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI) (, a pharmaceutical company focused on the discovery and development of patented dermatology products with their proprietary polymer delivery system Invisicare(R), today announced that Mr. Brian Piwek has been selected as a new member of the Company's Board of Directors replacing Mr. Jost Steinbruchel, who has resigned as a Board Member. Mr. Steinbruchel has been a Board Member since the company's inception in 1998 and the board and company officers wish to thank him for his valuable contribution during this time.



"We are delighted to have Mr. Brian Piwek join our Board of Directors, as he brings a great deal of experience and additional perspective that will be an asset to Skinvisible as we continue to implement our current initiatives," said Mr. Terry Howlett, President / CEO of Skinvisible. "We are entering an exciting phase at Skinvisible where we begin the commercialization of our dermatology products with international licensees. Brian's business development and retail expertise will be invaluable as Skinvisible continues to pursue its growth goals."

Brian Piwek's experience and expertise is in the international retail industry. He was president of Overwaitea Foods supermarket from 1991 until 1997. In 1997 Brian accepted the position as Co-CEO with A&P Canada (The Great Atlantic & Pacific Tea Company Inc.) and in 2000 was appointed Chairman, President and CEO of A&P Canada. In late 2002 he moved to the U.S. as President and Chief Executive Officer of A&P US (New York Stock Exchange symbol "GAP") where he began the turnaround of North America's oldest retail food chain. Brian retired from A&P in July 2005. Brian has been recognized for his achievements throughout his career including "President of the Year" by the Jim Pattison Group for the outstanding financial performance of Overwaitea in 1993. Brian is an MBA graduate and has served on many voluntary boards.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals, a wholly owned subsidiary of Skinvisible Inc., is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent.

About Invisicare(R)

Invisicare is a patented polymer delivery system developed to hold active ingredients topically on the skin for extended periods of time. A key benefit is that Invisicare is non-occlusive on the skin, allowing normal skin respiration and perspiration. The Company has developed a portfolio of topical products using Invisicare for the dermatology and cosmeceutical industries.

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending December 31, 2007).

Corporate Contact:

Terry Howlett, President/CEO

Skinvisible Pharmaceuticals, Inc

Phone: 702-433-7154


SOURCE Skinvisible, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Skinvisible Announces Licensing Agreement for Adapalene
2. Skinvisible Signs Marketing Agreement for India
3. Skinvisible Appoints Dr. George Korkos to Its Advisory Board
4. Skinvisible to Present at Merriman Curhan Ford & Co.s Investor Summit 2007
5. Tigris Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
6. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
7. Crdentia Appoints Charlie Mayhone to Director of Operations for its National Travel Division and Charlotte, North Carolina Market
8. National Institutes of Health Appoints Timothy C. Birdsall, ND to CAM Advisory Council
9. CPF Appoints Mishka Michon Chief Executive Officer
10. QualityMetric Appoints Chief Innovation and Research Officer
11. Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: